PharmTech Drug Digest 11.20
News|Articles|August 12, 2016

New NIH Grant to Focus on AIDS Vaccine Characterization and Manufacturing

The work will focus on addressing a key bottleneck to progress: he complexity and instability of HIV envelope proteins, which has limited the amount of material that can be evaluated in clinical trials.

A $98-million, seven-year contract will fund work to improve manufacturing, at the International AIDS Vaccine Initiative

The US National Institutes of Health’s National Institute of Allergy and Infectious Diseases, has awarded the International AIDS Vaccine Initiative (IAVI) a $98-million, seven-year contract to help speed the development of AIDS vaccine candidates.

The contract covers a range of product development services to advance the characterization and manufacturing of HIV envelope protein immunogens, which has been a focus of IAVI’s research efforts.

Manufacturing of these immunogens has proven difficult, given the complexity and instability of HIV envelope proteins.  This has limited the amount of material that can be evaluated in clinical trials. Optimizing HIV vaccine manufacturing would accelerate the development and evaluation of promising candidates.

IAVI and NIAID have been partnering closely in AIDS vaccine research for many years, including in the design and development of HIV envelope immunogens designed to trigger protective antibody responses.

Source: International AIDS Vaccine Initiative

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.